Pluri Inc.
About Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.3M
- Net income
- -$22.6M
- Total assets
- $38.7M
- Market cap
- $25.5M
- Gross margin
- 49.0%
- Operating margin
- -1659.9%
- Net margin
- -1740.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.3M
- Cost of revenue
- $682.0K
- Gross profit
- $654.0K
- Operating expenses
- $22.8M
- Operating income
- -$22.2M
- Income tax
- -$5.0K
- Net income
- -$23.2M
- EPS (basic)
- $-3.56
- EPS (diluted)
- $-3.56
Balance sheet
- Total assets
- $38.7M
- Current assets
- $22.1M
- Total liabilities
- $39.5M
- Current liabilities
- $32.3M
- Shareholders’ equity
- -$865.0K
Cash flow
- Operating cash flow
- -$18.2M
- Investing cash flow
- $8.0M
- Financing cash flow
- $9.5M
- Net cash flow
- -$475.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $25.5M
- EPS (diluted)
- $-3.56
- Shares outstanding
- 11.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 9, 1991
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $22.6M in FY2025.
- Revenue grew 366% from FY2023 to FY2025.
- Gross margin of 49.0%, net margin -1740.3%.
- Trading 60% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Pluri Inc..
Write a review
News about Pluri Inc.
News & sentiment via Polygon.io
